JPMorgan Chase & Co. Sells 3,403 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

JPMorgan Chase & Co. lowered its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 40.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,003 shares of the medical instruments supplier's stock after selling 3,403 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.09% of Mesa Laboratories worth $660,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of MLAB. Franklin Resources Inc. boosted its stake in shares of Mesa Laboratories by 27.8% during the third quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier's stock valued at $828,000 after purchasing an additional 1,403 shares during the period. Barclays PLC grew its position in shares of Mesa Laboratories by 357.4% in the 3rd quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier's stock worth $1,148,000 after buying an additional 6,905 shares during the period. Principal Financial Group Inc. increased its stake in shares of Mesa Laboratories by 21.8% during the third quarter. Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier's stock valued at $4,559,000 after purchasing an additional 6,292 shares in the last quarter. Pacer Advisors Inc. increased its position in Mesa Laboratories by 4.3% during the 4th quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock valued at $231,000 after buying an additional 73 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of Mesa Laboratories by 8.3% during the fourth quarter. Conestoga Capital Advisors LLC now owns 573,037 shares of the medical instruments supplier's stock valued at $75,566,000 after acquiring an additional 43,927 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Gary M. Owens sold 21,000 shares of Mesa Laboratories stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the sale, the chief executive officer now owns 43,337 shares of the company's stock, valued at approximately $5,369,887.67. This trade represents a 32.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.40% of the company's stock.

Mesa Laboratories Stock Up 3.2 %

NASDAQ MLAB traded up $3.66 during mid-day trading on Friday, reaching $119.06. The stock had a trading volume of 27,293 shares, compared to its average volume of 39,292. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $155.12. The stock has a market cap of $646.97 million, a PE ratio of -2.57 and a beta of 0.97. The company has a fifty day moving average price of $120.91 and a 200 day moving average price of $126.74.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. On average, research analysts expect that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Stockholders of record on Friday, May 30th will be given a dividend of $0.16 per share. The ex-dividend date is Friday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.54%. Mesa Laboratories's payout ratio is currently -1.38%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.